GlassScriptPhysician profile
Brian Patrick Ceballos
NPI 1811664584
$510.72
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $324 · 2024: $38.77 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $148.05 | 2025 | Attruby |
| Novo Nordisk INC | $115.62 | 2023 | Wegovy, Saxenda |
| Abbvie INC. | $31.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.38 | 2023 | |
| Impel Pharmaceuticals INC. | $22.04 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $21.33 | 2023 | Auvelity |
| Exact Sciences Corporation | $20.98 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $19.73 | 2023 | Trintellix |
| Boston Scientific Corporation | $19.55 | 2024 | |
| Medtronic, INC. | $19.22 | 2024 | Interstim |
| Idorsia Pharmaceuticals US INC | $17.76 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $17.73 | 2023 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $17.03 | 2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.80 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ceballos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.